# Merck Sharp & Dohme LLC: Phase 2 study started recruiting, 480 planned (Malignant Neoplam, Advanced Solid Tumors)

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) |
| NCT ID | NCT07793942 |
| Phase | Phase 2 |
| Status | recruiting |
| Conditions | Malignant Neoplam; Advanced Solid Tumors |
| Intervention types | biological, drug |
| Target enrollment | 480 |
| Site countries | United States, Canada, Switzerland |
| Posted | 2026-08-31 |
| Planned start | 2026-10-21 |
| Event | Started recruiting |
| Event date | 2026-10-21 |
| Last update posted | 2026-11-05 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Just started recruiting: sites, recruitment and supply are active.
- Phase 2: multi-site, larger budget.
- 480 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07793942). Last refreshed: 2026-11-06T09:49:51.899Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.